hrp0086p1-p253 | Diabetes P1 | ESPE2016

Sulphonylurea Treatment in a Patient with Intermediate DEND Syndrome

Catli Gonul , Kocyigit Cemil , Gencpinar Pinar , Can Penbe S. , Dundar Nihal O. , Dundar Bumin N.

Background: DEND syndrome is characterized by developmental delay, epilepsy, and neonatal diabetes mellitus (NDM) due to mutations in KCNJ11 and ABCC8 genes. Intermediate DEND (iDEND) syndrome is a rare mild form with mild motor, speech or cognitive delay and an absence of epilepsy. Improvement in glycemic control and neurologic symptoms has been reported in three cases with iDEND syndrome.Objective and hypotheses: To present the result...